Pfizer has launched Zavicefta (ceftazidime-avibactam) for adults hospitalised with serious infections caused by aerobic Gram-negative bacteria. Zavicefta combines the beta-lactam antibiotic ceftazidime with the beta-lactamase inhibitor, avibactam.

Pfizer says that ceftazidime-avibactam is effective against some “resistant aerobic Gram-negative pathogens of greatest global concern”, such as carbapenem-resistant Enterobacteriaceae and multi-drug resistant Pseudomonas aeruginosa.

Recommended

Quadrivalent flu jab launched

Sanofi Pasteur recently launched a quadrivalent influenza vaccine in the UK that protects against two A and two B strain...

Verapamil for rhinosinusitis?

Verapamil dramatically improves symptom scores in patients with chronic rhinosinusitis and nasal polyps

Popular

Proposed Nov concession prices sent to PSNC

PSNC has received a list of proposed concession prices for 52 of the 67 outstanding requests for November

Legislation finally passed on inadvertent dispensing errors

Pharmacy bodies have welcomed the legislation to introduce a new defence for inadvertent dispensing errors

PDA launches charter and campaign for safer pharmacies

The PDA has launched a Safer Pharmacies Charter with the aim of improving patient safety through better working conditio...